Quick Answer
IGC Pharma, Inc. reported Long Term Debt of $134.0 thousand for the year ending 2025.
- IGC Pharma, Inc. showed a decrease of -2.2% in Long Term Debt from 2024 to 2025.
- This data is from IGC Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on June 27, 2025.
- XBRL data for this metric is available from 2014 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2015: $308.2 thousand | Q3 2015: $294.7 thousand | Q4 2015: $648.1 thousand | Q2 2016: $596.3 thousand | Q3 2016: $653.8 thousand | Q4 2016: $446.0 thousand | Q1 2017: $452.1 thousand | Q2 2017: $176.0 thousand | Q3 2017: $350.8 thousand | Q4 2017: $0.00 | Q2 2020: $630.0 thousand | Q3 2020: $384.0 thousand | Q4 2020: $328.0 thousand | Q2 2021: $147.0 thousand | Q3 2021: $146.0 thousand | Q4 2021: $145.0 thousand | Q2 2022: $143.0 thousand | Q3 2022: $142.0 thousand | Q4 2022: $141.0 thousand | Q2 2023: $140.0 thousand | Q3 2023: $139.0 thousand | Q4 2023: $138.0 thousand | Q2 2024: $136.0 thousand | Q3 2024: $135.0 thousand | Q4 2024: $134.0 thousand | Q1 2025: $134.0 thousand | Q2 2025: $133.0 thousand | Q3 2025: $132.0 thousand.
- Historical annual values: Fiscal year 2025: $134.0 thousand | Fiscal year 2024: $137.0 thousand | Fiscal year 2023: $141.0 thousand | Fiscal year 2022: $144.0 thousand | Fiscal year 2021: $276.0 thousand | Fiscal year 2020: $0.00 | Fiscal year 2017: $452.1 thousand | Fiscal year 2016: $801.5 thousand | Fiscal year 2015: $323.9 thousand | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: